Suchergebnisse - "Buti, Maria"

PubPharm (44)

1

mTOR inhibitors a potential predisposing factor for chronic hepatitis E : Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)

enthalten in: Gastroenterologia y hepatologia | 2023

von Riveiro-Barciela, M. | Roade, L. | Martínez-Camprecios, J. | +21

2

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

enthalten in: The New England journal of medicine | 2022

von Yuen, M. | Lim, S. | Plesniak, R. | +132

CommentIn: N Engl J Med. 2022 Nov 24;387(21):1996-1998. - PMID 36346068

3

Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients : a Promising Marker of Infection Follow-Up

enthalten in: Microbiology spectrum | 2022

von Cortese, M. | Riveiro-Barciela, M. | Tabernero, D. | +16

4

Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1 : Conservation and Variability

enthalten in: Viruses | 2022

von Pacin-Ruiz, B. | Cortese, M. | Tabernero, D. | +15

5

Unexpected long-lasting anti-HEV IgM positivity : Is HEV antigen a better serological marker for hepatitis E infection diagnosis?

enthalten in: Journal of viral hepatitis | 2020

von Riveiro-Barciela, M. | Rando-Segura, A. | Barreira-Díaz, A. | +8

6

Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals

enthalten in: Journal of hepatology | 2020

von Pons, M. | Rodríguez-Tajes, S. | Esteban, J. | +8

CommentIn: J Hepatol. 2020 Aug;73(2):472-473. - PMID 32493575

7

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis : The EXPEDITION-8 trial

enthalten in: Journal of hepatology | 2020

von Brown, R. | Buti, M. | Rodrigues, L. | +19

CommentIn: J Hepatol. 2020 Mar;72(3):389-390. - PMID 31703944

8

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6

enthalten in: Journal of viral hepatitis | 2019

von Lawitz, E. | Gane, E. | Feld, J. | +56

9

Treating chronic hepatitis delta : The need for surrogate markers of treatment efficacy

enthalten in: Journal of hepatology | 2019

von Yurdaydin, C. | Abbas, Z. | Buti, M. | +34

10

HEVnet : a One Health, collaborative, interdisciplinary network and sequence data repository for enhanced hepatitis E virus molecular typing, characterisation and epidemiological investigations

enthalten in: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin | 2019

von Mulder, A. | Kroneman, A. | Franz, E. | +46

1
2
3
4
5
Nächster »
[5]